期刊文献+

复方环丙沙星栓联合云南白药、宁泌泰治疗组织学前列腺炎伴PSA升高患者的疗效评价 被引量:15

Compound ciprofloxacin suppository combined with Ningbitai and Yunnan Baiyao for histological prostatitis with PSA elevation
原文传递
导出
摘要 目的:评价复方环丙沙星栓联合宁泌泰、云南白药治疗组织学前列腺炎并伴有PSA升高患者的效果。方法:收集2010年9月~2012年4月期间,在门诊诊断为ⅢA型前列腺炎并伴有4μg/L<PSA<50μg/L的患者150例。经左氧氟沙星片0.5 g口服(1次/d)治疗1个月后,PSA仍高于正常的患者86例行B超引导下前列腺穿刺活检,排除前列腺癌并明确前列腺炎病理诊断65例。对65例符合入选标准患者,按照治疗方式的不同分为实验组和对照组,实验组45例,均接受云南白药胶囊(2次/d,1粒/次)、宁泌泰胶囊(3次/d,4粒/次)联合复方环丙沙星栓(2次/d,早晚各1枚)塞肛治疗4周,对照组20例仅接受复方环丙沙星栓联合宁泌泰的治疗。分别于治疗前后行PSA检测和填写慢性前列腺炎症状指数评分(NIH-CPSI)问卷,结合直肠超声检查,分析治疗前后PSA相关值及CPSI的变化,并对两组间PSA及CPSI变化进行比较。结果:两组患者人口统计学及基线资料相似。两组患者治疗前后PSA、前列腺特异性抗原密度(PSAD)、CPSI差异均有统计学意义(P<0.05﹚,两组间PSA及CPSI变化率比较差异有统计学意义(P=0.029和0.001)。结论:复方环丙沙星栓联合云南白药、宁泌泰治疗,可使组织学已确诊并伴有PSA升高的ⅢA型前列腺炎患者PSA水平明显下降,症状显著缓解;合用云南白药可显著协同增强联合疗法治疗慢性前列腺炎的治疗效果。 Objective: To explore the efficacy of compound ciprofloxacin suppository (CCS) combined with Ningbitai (NBT) and Yunnan Baiyao (YB) capsules in the treatment of histological prostatitis with elevated levels of PSA. Methods: This study in- cluded 150 cases of type Ilia histological prostatitis, with PSA levels ranging from 4 to 50 μg/L. After 1 months treatment with oral Levofloxaein tablets at 0.5 g qd, the PSA levels remained high in 86 patients. Prostate cancer was excluded by transrectal ultrasound- guided prostatic biopsy, and histological prostatitis was confirmed in 65 patients, who were assigned to an experimental group ( n = 45 ) and a control group (n =20) to receive CCS combined with NBT and YB capsules and CCS with NBT only, respectively, both for 4 weeks. We determined the PSA levels, obtained NIH-CPSI scores before and after medication, and compared them between the two groups. Results: The two groups were well balanced in demographics and baseline characteristics. After treatment, both showed signifieant differences in the PSA level, PSA density (PSAD) and CPSI scores from the baseline (P 〈 0.05 ), and there were also statis- tically significant differences between the two groups in the changes of the PSA level and CPSI scores after medication (P = 0.029 and O. 001 ). Conclusion: Compound ciprofloxacin suppository combined with Ningbitai and Yunrtan Baiyao capsules can significantly decrease the level of serum PSA and relieve related symptoms in III A histological prostatitis with PSA elevation, and Yunnan Baiyao capsules can significantly enhance the therapeutic effect.
出处 《中华男科学杂志》 CAS CSCD 2012年第11期986-990,共5页 National Journal of Andrology
关键词 前列腺炎 复方环丙沙星栓 云南白药胶囊 宁泌泰胶囊 prostatitis compound ciprofloxacin suppository Yunnan Baiyao capsule Ningbitai capsule
  • 相关文献

参考文献21

  • 1Haas GP, Delongchamps N, Brawley OW, et al. The worldwide epidemiology of prostate cancer: Perspectives from autopsy studies. Can J Urol, 2008, 15(1) : 3866-3871.
  • 2Turner JA, Ciol MA, Von Korff M, et 02. Healtheare use and costs of primary and secondary care patients with prostatitis. Urology, 2004, 63(6) : 1031-1035.
  • 3徐则乔,华立新,钱立新,吴宏飞.前列腺穿刺活检对血清前列腺特异抗原值的影响[J].中华男科学杂志,2002,8(5):341-342. 被引量:4
  • 4McNaughton Collins M, Pontari MA, OLeary MP, et al. Quality of life is impaired in men with chronic prostatitis: The Chronic Prostatitis Collaborative Research Network. J Gen Intern Med, 2001, 16(10) : 656-662.
  • 5McNaughton Collins M, MacDonald R, Wilt TJ. Diagnosis and treatment of chronic abaeterial prostatitis: A systematic review. Ann Intern Med, 2000, 133(5) : 367-381.
  • 6Zhou Z, Hong L, Shen X, et al. Detection of nanobacteria infec- tion in type III prostatitis. Urology, 2008, 71(6) : 1091-1095.
  • 7Naber KG, Theuretzbacher U, Moneva-Koucheva G, et al. Uri- nary excretion and bactericidal activity of intravenous ciprofloxa- cin compared with oral ciprofloxacin. Eur J Clin Microbiol Infect Dis, 1999, 18(11):783-789.
  • 8Aghazarian A, Plas E, Stancik I, et al. New method for differen- tiating chronic prostatitis./chronic pelvic pain syndrome Ilia from IIIB involving seminal macrophages and monocytes. Urology, 2011, 78(4) : 918-923.
  • 9He L, Wang Y, Long Z, et al. Clinical significance of IL-2, IL- l0, and TNF-alpha in prostatic secretion of patients with chronic prostatifis. Urology, 2010, 75(3): 654-657.
  • 10Nickel JC, Pontari M, Moon T, et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol, 2003, 169(4) : 1401-1405.

二级参考文献1

共引文献15

同被引文献147

引证文献15

二级引证文献128

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部